Amplia Therapeutics (ASX:ATX) Accounts Payable: A$1.40 Mil (As of Mar. 2026)


ASX:ATX Amplia Therapeutics Ltd ASX:ATX
36 GF Score
Price A$0.16
! 2 Warning Signs
View Full Analysis

What is Amplia Therapeutics Accounts Payable?

Amplia Therapeutics ASX:ATX +3.33% 36 Accounts Payable is A$1.40 Mil as of Mar. 2026. GuruFocus rates ASX:ATX with a GF Score™ of 36/100. The stock has 2 warning signs investors should review.

Amplia Therapeutics's Accounts Payable for the quarter that ended in Mar. 2026 was A$1.40 Mil.

Amplia Therapeutics's quarterly Accounts Payable declined from Mar. 2025 (A$1.56 Mil) to Sep. 2025 (A$1.12 Mil) but then increased from Sep. 2025 (A$1.12 Mil) to Mar. 2026 (A$1.40 Mil).

Amplia Therapeutics's annual Accounts Payable declined from Mar. 2024 (A$1.60 Mil) to Mar. 2025 (A$1.56 Mil) and declined from Mar. 2025 (A$1.56 Mil) to Mar. 2026 (A$1.40 Mil).

Amplia Therapeutics Accounts Payable Related Terms

Amplia Therapeutics Accounts Payable Historical Data

* Premium members only.

The historical data trend for Amplia Therapeutics's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amplia Therapeutics Accounts Payable Chart

Amplia Therapeutics Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.37 0.35 1.60 1.56 1.40

Amplia Therapeutics Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.60 1.31 1.56 1.12 1.40
ASX:ATX
36GF Score
Amplia Therapeutics Ltd ASX:ATX
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amplia Therapeutics Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of A$1.40 Mil mean?
Amplia Therapeutics (ASX:ATX) has a Accounts Payable of A$1.40 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Amplia Therapeutics and its competitors.
Is Amplia Therapeutics' Accounts Payable too high?
Amplia Therapeutics' current Accounts Payable is A$1.40 Mil. Overall, Amplia Therapeutics has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Amplia Therapeutics' Accounts Payable compare to VRTX and REGN?
Amplia Therapeutics' Accounts Payable of A$1.40 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Amplia Therapeutics and its competitors. Amplia Therapeutics's current Accounts Payable is A$1.40 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amplia Therapeutics stock overvalued right now?
Amplia Therapeutics (ASX:ATX) has a current Accounts Payable of A$1.40 Mil. The current Accounts Payable is A$1.40 Mil. Amplia Therapeutics' overall GF Score™ is 36/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Amplia Therapeutics (ASX:ATX), the current Accounts Payable is A$1.40 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Amplia Therapeutics Business Description

Other Exchanges INNMF:USA
Address 90 William Street, Level 5, Melbourne, VIC, AUS, 3000
Amplia Therapeutics Ltd is an Australian, clinical-stage, drug development company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. The company is focused on the development of these drug candidates for potential use in multiple indications in oncology (e.g. pancreatic cancer) and chronic fibrotic diseases. Its molecule, AMP945 is a selective and potent inhibitor of FAK and is currently in a phase 2 clinical trial for pancreatic cancer, in clinical development for ovarian cancer, and preclinical development for idiopathic pulmonary fibrosis (IPF).
36GF Score

Get the complete analysis for ASX:ATX

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.16
Price